Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

Antonino Musolino,Fabio Falcini,Angelica Sikokis,Daniela Boggiani,A. Rimanti,Benedetta Pellegrino,Enrico Maria Silini,N Campanini,E. Barbieri,Claudio Zamagni,R. Degli Esposti,Laura Cortesi,Giancarlo Bisagni,L Cavanna,Antonio Frassoldati,Paolo Sgargi,Maria Michiara

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

2018

Antonino Musolino
Fabio Falcini
Angelica Sikokis
Daniela Boggiani
A. Rimanti
Benedetta Pellegrino
Enrico Maria Silini
N Campanini
E. Barbieri
Claudio Zamagni
R. Degli Esposti
Laura Cortesi
Giancarlo Bisagni
L Cavanna
Antonio Frassoldati
Paolo Sgargi
Maria Michiara

• pT1a N0M0 human epidermal growth factor receptor 2 (HER2)-positive interval cancers have a poorer outcome than HER2-positive screen-detected (SD) cancers.

Keywords:

Breast cancer
Cancer registry
Cancer
Epidemiology of cancer
Interval cancer
Population
Oncology
Medicine
Internal medicine
Human Epidermal Growth Factor Receptor 2
Prognostic variable
Trastuzumab
Confidence interval

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations